Akero Therapeutics to Present at the Jefferies London Healthcare Conference

Rhea-AI Summary

Akero Therapeutics (Nasdaq: AKRO) announced participation in a fireside chat at the Jefferies London Healthcare Conference, available for on-demand viewing on November 18 at 3:00 a.m. EST. Known for its focus on serious metabolic diseases, Akero is developing efruxifermin (EFX), a potential best-in-class treatment for non-alcoholic steatohepatitis (NASH), which currently lacks approved therapies. EFX is undergoing evaluation in two Phase 2b trials: HARMONY and SYMMETRY.

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference which will be available for on-demand viewing starting Thursday, November 18 at 3:00 a.m. EST.

A webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com.

About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), is a differentiated Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body. EFX is designed to offer convenient once-weekly subcutaneous dosing. The consistency and magnitude of observed effects position EFX to be a potentially best-in-class medicine, if approved, for treatment of NASH. EFX is currently being evaluated in two Phase 2b clinical trials: the HARMONY study in pre-cirrhotic patients with F2/F3 fibrosis and the SYMMETRY study in compensated cirrhotic (F4) patients. Akero is headquartered in South San Francisco. Visit us at www.akerotx.com for more information.

Investor Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina.tartaglia@sternir.com

Media Contact:
650.487.6488
media@akerotx.com

FAQ

What is the date and time of Akero's participation in the Jefferies London Healthcare Conference?

Akero Therapeutics will participate in the Jefferies London Healthcare Conference on November 18, 2021, at 3:00 a.m. EST.

Where can I watch the Akero Therapeutics presentation from the conference?

The presentation will be available for on-demand viewing through the investor relations section of Akero's website.

What is efruxifermin (EFX) being developed for by Akero?

Efruxifermin (EFX) is being developed as a treatment for non-alcoholic steatohepatitis (NASH), a serious metabolic disease.

What clinical trials is Akero currently conducting for EFX?

Akero is conducting two Phase 2b trials: the HARMONY study for pre-cirrhotic patients and the SYMMETRY study for compensated cirrhotic patients.

What is the significance of the Jefferies London Healthcare Conference for Akero?

The conference allows Akero Therapeutics to showcase its advancements and engage with investors and healthcare professionals.